Skip to main content

Advertisement

Log in

The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Young breast cancer patients have a poorer prognosis, especially when their tumors are hormone receptor positive. We analyzed the association between Ki67 and age and the impact of these factors on outcomes in hormone receptor-positive breast cancer.

Methods

The records of 9,321 hormone receptor-positive invasive breast cancer patients from three large centers were retrospectively reviewed. Each institution separately assayed Ki67 level immunohistochemically. Univariate and multivariate analysis for recurrence-free survival (RFS) was performed on 4,738 patients from a single center.

Results

Ki67 level was inversely proportional to age in all three data sets and was significantly higher for younger patients (p < 0.001, 0.03, and <0.001, respectively). This correlation was seen only in the human epidermal growth factor receptor 2 (HER2)-negative population. Survival analysis showed that both very young age (<35 years) and high Ki67 level (≥10 %) were independent prognostic factors. Although young age was a worse prognostic indicator regardless of HER2 status, Ki67 index was associated with worse prognosis only in HER2-negative patients. When patients were stratified into those with low and high Ki67, young age remained a significant factor for RFS, with hazard ratios in these two Ki67 groups of 2.15 and 2.57, respectively (p < 0.001). Also, the young age/low Ki67 group had significantly poorer RFS than the older age/high Ki67 group (p < 0.001).

Conclusions

Ki67 level was higher in younger patients. However, very young patients had a poorer prognosis regardless of Ki67 level. Unknown biologic factors other than high cell proliferation might play a role in the aggressiveness of hormone receptor-positive breast cancer in very young patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Narod SA. Breast cancer in young women. Nat Rev Clin Oncol. 2012;9:460–70.

    Article  CAS  PubMed  Google Scholar 

  2. Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688–97.

    CAS  PubMed  Google Scholar 

  3. Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131:1061–6.

    Article  CAS  PubMed  Google Scholar 

  4. Rubino C, Arriagada R, Delaloge S, et al. Relation of risk of contralateral breast cancer to the interval since the first primary tumour. Br J Cancer. 2010;102:213–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Bharat A, Aft RL, Gao F, et al. Patient and tumor characteristics associated with increased mortality in young women (< or = 40 years) with breast cancer. J Surg Oncol. 2009;100:248–51.

    Article  PubMed  Google Scholar 

  6. Morrison DH, Rahardja D, King E, et al. Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. Br J Cancer. 2012;107:382–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26:3324–30.

    Article  PubMed  Google Scholar 

  8. Adami HO, Malker B, Holmberg L, et al. The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986;315:559–63.

    Article  CAS  PubMed  Google Scholar 

  9. Azim HA Jr, Michiels S, Bedard PL, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18:1341–51.

    Article  CAS  PubMed  Google Scholar 

  10. Kim EK, Noh WC, Han W, et al. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg. 2011;35:1244–53.

    Article  PubMed  Google Scholar 

  11. Ahn SH, Son BH, Kim SW, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol. 2007;25:2360–8.

    Article  PubMed  Google Scholar 

  12. Goldhirsch A, Colleoni M, Gelber RD. Endocrine therapy of breast cancer. Ann Oncol. 2002;13(Suppl 4):61–8.

    Article  PubMed  Google Scholar 

  13. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000;355:1869–74.

    Article  CAS  PubMed  Google Scholar 

  14. Colleoni M, Rotmensz N, Peruzzotti G, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006;17:1497–503.

    Article  CAS  PubMed  Google Scholar 

  15. Liu YR, Jiang YZ, Yu KD, et al. Different patterns in the prognostic value of age for breast cancer–specific mortality depending on hormone receptor status: a SEER population-based analysis. Ann Surg Oncol. In press.

  16. Dai H, van’t Veer L, Lamb J, et al. (2005) A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 65:4059–66.

    Article  CAS  PubMed  Google Scholar 

  17. Perreard L, Fan C, Quackenbush JF, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006;8:R23.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Choi DH, Kim S, Rimm DL, et al. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J. 2005;11:404–11.

    Article  PubMed  Google Scholar 

  19. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13:73–80.

    Article  CAS  PubMed  Google Scholar 

  20. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.

    Article  CAS  PubMed  Google Scholar 

  21. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–5.

    CAS  PubMed  Google Scholar 

  22. Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103:1656–64.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.

    Article  CAS  PubMed  Google Scholar 

  24. Jung SY, Han W, Lee JW, et al. Ki-67 expression gives additional prognostic information on St Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol. 2009;16:1112–21.

    Article  PubMed  Google Scholar 

  25. Cha Y, Han SW, Seol H, et al. Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Res. 2014;34:4275–80.

    PubMed  Google Scholar 

  26. Han W, Kang SY; Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat. 2010;119:193–200.

    Article  PubMed  Google Scholar 

  27. Cancello G, Maisonneuve P, Mazza M, et al. Pathological features and survival outcomes of very young patients with early breast cancer: how much is “very young”? Breast. 2013;22:1046–51.

    Article  PubMed  Google Scholar 

  28. Anders CK, Fan C, Parker JS, et al. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol. 2011;29:e18–20.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Polley MY, Leung SC, McShane LM, et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013;105:1897–906.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgment

Supported in part by a National Research Foundation of Korea (NRF) Grant funded by the Korea government (MSIP) (Grant 2012M3A9B2028834) and the SNUH Research Fund (Grant 04-2010-1150).

Disclosure

The authors declare no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wonshik Han MD, PhD.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 47 kb)

Supplementary material 2 (DOC 52 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, J., Han, W., Jung, SY. et al. The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women. Ann Surg Oncol 22, 3481–3488 (2015). https://doi.org/10.1245/s10434-015-4399-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-4399-1

Keywords

Navigation